PRISM MediaWire

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Top Line Data Expected Year-End 2024

12 August 2024

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

· Melanocortin receptors on neurons in the brain control feeding and weight loss

9 August 2024

Oncocyte Announces August Investor Conferences Participation

IRVINE, Calif., August 5, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August:

5 August 2024

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

PITTSBURGH, PA, August 1, 2024 – PRISM MediaWire -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously...

1 August 2024

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET

1 August 2024

Artificial Intelligence:

AI Datacenters and Infrastructure May Be the Next AI Related Play. Here’s Where to Look

New York, July 24, 2024 - PRISM MarketView - As artificial intelligence (AI) continues to grow in significance, the infrastructure supporting AI technologies has also evolved. This also opens a new door for opportunities related to AI as investors look to boost portfolio...

24 July 2024

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jackson Center, PA July 24, 2024 – PRISM MediaWire -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of tr...

24 July 2024

Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

· Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP)

22 July 2024

ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments

Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives

9 July 2024

SIPP Industries Announces Strategic Acquisition of Revenue Share in Calypso Pharmaceuticals to Bolster Position in Cannabis and Hemp Industries

COSTA MESA, CA, May 1, 2024 – PRISM MediaWire - Sipp Industries, Inc. (OTC: SIPC), a leading player in the cannabis and hemp industries, announces its strategic acquisition of revenue share in Calypso Pharmaceuticals, a Texas-based company renowned for its innovative pro...

1 May 2024